Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open Label, Randomized, 3 Arm Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab as First Line Therapy for Locally Recurrent or Metastatic Breast Cancer

NCT00370552 is registered in ClinicalTrials.gov with R-Pharm as lead sponsor.

NCT NCT00370552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00370552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open Label, Randomized, 3 Arm Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab as First Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Lead sponsor
R-Pharm
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2007
Completion date
November 30, 2009
Enrollment
136 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer